drugset / Trial / NCT05267470
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in combination with other anti-cancer therapies.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
Outcome
Outcome not reported
Stopped (Business): “Business decision not due to safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemarituzumab | Monoclonal antibody | — | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |